EPRISTERIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H37NO3
Molecular Weight	399.5662
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC=C4C=C(CC[C@]34C)C(O)=O

InChI

InChIKey=VAPSMQAHNAZRKC-PQWRYPMOSA-N

InChI=1S/C25H37NO3/c1-23(2,3)26-21(27)20-9-8-18-17-7-6-16-14-15(22(28)29)10-12-24(16,4)19(17)11-13-25(18,20)5/h6,14,17-20H,7-13H2,1-5H3,(H,26,27)(H,28,29)/t17-,18-,19-,20+,24-,25-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C25H37NO3
Molecular Weight	399.5662
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/18465521

Epristeride is a steroid 5-alpha-reductase inhibitor developed for the treatment of prostatic hyperplasia and acne. The drug reached phase III clinical trial for hyperplasia in the UK, the US and Japan, however, the current status of the drug is unknown.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
3-oxo-5-alpha-steroid 4-dehydrogenase 2 1 Target ID: P31213 Gene ID: 6716.0 Gene Symbol: SRD5A2 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/9268084	Inhibitor 8297		11.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Prostatic hyperplasia 4 Sources: http://www.ncbi.nlm.nih.gov/pubmed/18465521	Primary		Phase III 656	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Effects of steroid 5alpha-reductase inhibitor ONO-9302 and anti-androgen allylestrenol on the prostatic growth, and plasma and prostatic hormone levels in rats.	1997 Jul	9268084
Mutagenicity tests on epristeride in vitro and in vivo.	1998 Nov	10437149
Effect of epristeride on expression of TGF-beta receptor in rat prostatic epithelial cells in vitro.	2001 Jun	11747757
Inhibition of cultured rat prostatic epithelial cell growth by epristeride in vitro.	2001 Mar	11742574
Atrophy and apoptosis in ventral prostate of rats induced by 5alpha-reductase inhibitor, epristeride.	2001 May	11743885
Inhibition of regrowth of prostatic glandular cells by epristeride.	2001 Sep	11749869

Patents

Sample Use Guides

In Vivo Use Guide

Epristeride tablets, 5 mg p.o., twice daily for 120 days.

Route of Administration: Oral

In Vitro Use Guide

Stromal cell proliferation in response to testosterone was dose-dependently inhibited by epristeride (1 x 10(-9) -3 x 10(-7) M, P < 0.05).

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:52:21 GMT 2023` Edited by `admin` on `Fri Dec 15 15:52:21 GMT 2023`
Record UNII	39517A04PS
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EPRISTERIDE

Official Name

English

Epristeride [WHO-DD]

Common Name

English

EPRISTERIDE [MI]

Common Name

English

ANDROSTA-3,5-DIENE-3-CARBOXYLIC ACID, 17-(((1,1-DIMETHYLETHYL)AMINO)CARBONYL)-, (17.BETA.)-

Common Name

English

SK&F-105657

Code

English

SK&F 105657

Code

English

17β-(tert-Butylcarbamoyl)androsta-3,5-diene-3-carboxylic acid

Systematic Name

English

EPRISTERIDE [JAN]

Common Name

English

epristeride [INN]

Common Name

English

EPRISTERIDE [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2319